Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Class Action Against TransMedics Group, Inc. (NASDAQ: TMDX)

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, alleging misleading statements and illegal business practices that negatively impacted the company's financial performance and stock price [1][3]. Group 1: Lawsuit Details - The lawsuit was filed by Scott+Scott Attorneys at Law LLP in the U.S. District Court for the District of Massachusetts, asserting claims under the Securities Exchange Act of 1934 [1]. - The class action includes all individuals who purchased TransMedics securities between February 28, 2023, and January 10, 2025, and were harmed as a result [1][6]. Group 2: Allegations Against TransMedics - Defendants are accused of failing to disclose reliance on illegal and coercive business practices, including kickbacks, billing fraud, and overcharging patients, which led to a decline in customer usage and increased regulatory scrutiny [3]. - The company experienced its first sequential revenue decline since Q3 2021, with a significant drop in stock price following the announcement of its Q3 2024 financial results [4]. Group 3: Impact on Stock Price - Following the release of a report by Scorpion Capital on January 10, 2025, which accused TransMedics of overbilling hospitals, the stock price fell by $3.74 per share, or 5.15$68.81 [5]. - The stock continued to decline, falling an additional $4.76 per share, or 6.9$64.05 on January 13, 2025 [5].